Dapagliflozin-Based Therapies in Patients With Type 2 Diabetes Mellitus in an Outpatient Real-World Setting Across India: The DAPATURN Study
AIM: Determination of usage patterns and clinical profile of patients receiving dapagliflozin and its combinations in outpatient settings across India. METHODS: An observational, cross-sectional study was conducted across 661 sites in four zones of India from March to December 2024. Baseline demographics, comorbidities, and used dapagliflozin formulations (dual or triple fixed-dose combination (FDC)) were recorded to analyze usage patterns. RESULT: = 4,192, 34.96%). CONCLUSIONS: This study highlights real-world dapagliflozin use in India, showing that dapagliflozin-based FDCs are widely adopted across diverse patient groups.
Authors
- Mounam Chattopadhyay (ORCID: https://orcid.org/0000-0003-4136-6079)
- Ashwani Mehta (ORCID: https://orcid.org/0009-0006-3135-7303)
- Kaushik Rakshit
- Santosh Revenkar
- Rajeev Philip
- Kamlesh Patel
- Rajeev Chawla
- K. P. Singh
- Amber C Shinde
- Sowmiya M K.
- Sabeer T. K.
- Nikhil Motiramani
Institutions
- All India Institute of Medical Sciences Raipur (IN)
- Lupin Pharmaceuticals (India) (IN)
- Diabetes Australia (AU)
- Bangur Institute of Neurosciences (IN)
- Pushpagiri Medical College (IN)
- Health First (US)
- GD Hospital & Diabetes Institute (IN)
- Sir Ganga Ram Hospital (IN)
- Diabetes Foundation (IN)
- Fortis Hospital (IN)
- Sir Ganga Ram Hospital (PK)
Publication Details
- Journal
- Cureus
- Published
- 2026-04-06
- DOI
- https://doi.org/10.7759/cureus.106506
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00